JOHN F. FISHER, M.D.; D. MARK HENSON, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Inasmuch as amphotericin B remains standard therapy for most serious fungal infections, additional reports of resistance to this agent, particularly among yeast-like organisms, are disturbing. Therefore, we read with concern the report by Dick and colleagues (1) of a neutropenic patient who died of a candidal infection caused by an amphotericin B-resistant organism. The progressive depletion of cellular ergosterol levels in Candida guilliermondii isolates was well documented by these authors as the probable mechanism of amphotericin resistance. As the authors indicate, this finding substantiates their previous data (2).
We believe their case report raises an additional concern
FISHER JF, HENSON DM. Amphotericin B Resistance in Candida. Ann Intern Med. 1985;102:563–564. doi: 10.7326/0003-4819-102-4-563_4
Download citation file:
Published: Ann Intern Med. 1985;102(4):563-564.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use